Register
Journal Updates
eMediNexus Coverage from: 
Metformin Repurposed: Boosts Survival in TKI-Treated Lung Cancer
eMediNexus,  10 September 2019
remove_red_eye 565 Views
#Hematology #Oncology #Pharmacist #Radiology

1 Read Comments                

Adding metformin to standard inhibitors of epidermal growth factor receptor (EGFR) and tyrosine kinase inhibitors (TKIs) significantly improved both progression-free and overall survival in advanced lung adenocarcinoma – with no significant increase in adverse events, a randomized phase II study found.Investigators found a significantly longer median progression-free survival with EGFR-TKIs plus metformin: 13.1 months (95% CI 9.8-16.3) compared with 9.9 months (95% CI 7.5-12.2) for standard EGFR-TKIs (hazard ratio 0.60, 95% CI 0
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now